文献速递功能神经外科

磁共振引导聚焦超声小脑丘脑束切断术治疗慢性药物难治性特发性震颤:解剖靶点重新评估与临床结果

MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: anatomical target reappraisal and clinical results.
PubMed 文献 · J Neurosurg · 2020-02-07

该研究对10例连续慢性药物难治性特发性震颤患者行单侧磁共振引导聚焦超声小脑丘脑束切断术并随访1年,基于红核中心MR可视化与热剂量控制的预计划靶点子单元提出标准化靶向方案,结果显示震颤缓解率高且无出血或感染。

要点

  • 10例慢性药物难治性特发性震颤患者接受单侧MRgFUS小脑丘脑束切断术并随访1年。
  • CRST评分基线48±12,3个月16±7,1年17±8;患者评定手术侧震颤缓解2天95%、3个月96%、1年93%。
  • HF16基线11.0±2.1,3个月0.7±0.7,1年0.8±0.9(平均降低93%);1年ADL评分平均降低51%。

核心结论

  • 作者结果提示MRgFUS小脑丘脑束切断术对药物难治性特发性震颤是非常有效的治疗选择。

研究设计与样本

  • 10例连续慢性药物难治性特发性震颤患者接受单侧MRgFUS小脑丘脑束切断术并随访1年。
  • 基于红核中心MR可视化及热剂量控制下短声照射实现的预计划靶点子单元,提出MRgFUS小脑丘脑束切断术标准化靶向方案。
  • 计算43°C下18与240累积等效分钟的热剂量,并与术中及术后2天T2加权MR图像进行相关性分析。

主要发现

  • CRST评分基线均值±标准差为48±12,3个月为16±7,1年为17±8。
  • 患者评定手术侧震颤缓解2天后为95%,3个月为96%,1年为93%。
  • HF16基线为11.0±2.1,3个月为0.7±0.7,1年为0.8±0.9(平均降低93%);1年HF16最低降低78%。
  • 1年ADL评分平均降低51%。
  • 无出血或感染;仅串联步态可检测的步态困难在1年时3例增加、2例减少;无构音障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In addition to the well-recognized ventral intermediate nucleus (Vim) thalamotomy for the treatment of chronic therapy-resistant essential tremor (ET), an alternative approach targeting the posterior part of the subthalamus was proposed in the 1960s and early 1970s and then was reactualized as cerebellothalamic tractotomy (CTT) with the advent of MR-guided focused ultrasound (MRgFUS) surgery. The goal of this study was to improve target coverage and thus efficacy (i.e., tremor control and its consistency). The authors undertook a histological reappraisal of the CTT target and proposed a targeting strategy of the MRgFUS CTT based on 1) the MR visualization of the center of the red nucleus and 2) the application of preplanned target subunits realized with short sonications under thermal dose control. This study was aimed at demonstrating the efficacy and risk profile of this approach against chronic therapy-resistant ET. METHODS: Ten consecutive patients suffering from chronic therapy-resistant ET benefited from a unilateral MRgFUS CTT and were followed over the course of 1 year. Primary endpoints were subjective tremor relief, Clinical Rating Scale for Tremor (CRST) score, activities of daily living (ADL) score, and the hand function (HF) scores HF16 and HF32. Histological reappraisal of the target led the authors to propose a standardized targeting protocol for MRgFUS CTT. Thermal doses for 18 and 240 cumulative equivalent minutes at 43°C were calculated and correlated with intraoperative and 2 days postoperative T2-weighted MR images. RESULTS: The mean ± SD for the baseline CRST score was 48 ± 12; the score was 16 ± 7 at 3 months, and 17 ± 8 at 1 year. The mean tremor relief rated by the patients for the operated side was 95% after 2 days, 96% at 3 months, and 93% at 1 year. The mean HF16 was 11.0 ± 2.1 at baseline, 0.7 ± 0.7 at 3 months, and 0.8 ± 0.9 at 1 year (93% mean reduction). The minimum reduction for the HF16 at 1 year was 78%. There was a 51% reduction of the mean ADL score at 1 year. There was no bleeding or infection. Gait difficulties, only detectable on tandem gait, were increased in 3 patients and reduced in 2 patients at 1 year. There was no dysarthria. CONCLUSIONS: The authors' results suggest that MRgFUS CTT is a very effective treatment option for therapy-resistant ET.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Gallay MN, Moser D, Jeanmonod D, et al. MR-guided focused ultrasound cerebellothalamic tractotomy for chronic therapy-resistant essential tremor: anatomical target reappraisal and clinical results. J Neurosurg. 2020. PMID: 32032945. doi:10.3171/2019.12.JNS192219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。